Your browser doesn't support javascript.
loading
Production and Performance Assessment of a Severe Acute Respiratory Syndrome Coronavirus 2 Biomimetic in a Verification Program for Pandemic Readiness.
Machowski, Edith E; Reyneke, Anna E; Sher, Dean E; Kana, Bavesh D.
Affiliation
  • Machowski EE; Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical TB Research, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa.
  • Reyneke AE; SmartSpot Quality (Pty) Limited, Johannesburg, South Africa.
  • Sher DE; SmartSpot Quality (Pty) Limited, Johannesburg, South Africa.
  • Kana BD; Department of Science and Innovation/National Research Foundation Centre of Excellence for Biomedical TB Research, University of the Witwatersrand, National Health Laboratory Service, Johannesburg, South Africa. Electronic address: bavesh.kana@wits.ac.za.
J Mol Diagn ; 25(12): 907-912, 2023 12.
Article in En | MEDLINE | ID: mdl-37863192
ABSTRACT
During the early stages of the 2019 coronavirus disease (COVID-19) pandemic in South Africa, one of many challenges included availability of control material for laboratory proficiency testing programs. Proficiency testing control material using live severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or RNA extracted from cell culture was either biohazardous or costly, particularly in resource-limited settings. This study reports the development and application of a noninfectious SARS-CoV-2 biomimetic Mycobacterium smegmatis strain that mimics a positive result in the GeneXpert SARS-CoV-2 Xpert Xpress cartridge. Nucleotide sequences located in genes encoding the RNA-dependent RNA polymerase, the nucleocapsid, and the envelope proteins were used. The resulting biomimetic strain was prepared as a positive proficiency testing control and distributed in South Africa for verification of laboratories before their testing of clinical specimens. Between April and December 2020, a total of 151 GeneXpert instruments with 2532 modules were verified to bring COVID-19 mass testing in South Africa online. An average concordance of 98.6% was noted in the entire laboratory network, allowing identification of false-positive/false-negative results and instrument errors. This noninfectious, easily scalable proficiency testing control material became available within 2 months after the start of the pandemic in South Africa and represents a useful approach to consider for other diseases and future pandemics.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: En Journal: J Mol Diagn Journal subject: BIOLOGIA MOLECULAR Year: 2023 Type: Article Affiliation country: South Africa

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 Limits: Humans Language: En Journal: J Mol Diagn Journal subject: BIOLOGIA MOLECULAR Year: 2023 Type: Article Affiliation country: South Africa